{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:40:24Z","timestamp":1790815224081,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-019-1051-6","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T07:30:23Z","timestamp":1547191823000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":197,"title":["Fexinidazole: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"1051_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/7355_2011_17","volume":"7","author":"T Geldern Von","year":"2011","unstructured":"Von Geldern T, Harhay MO, Scandale I, et al. Kinetoplastid parasites. Top Med Chem. 2011;7:181\u2013242.","journal-title":"Top Med Chem."},{"key":"1051_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/bmb\/lds031","volume":"104","author":"MP Barrett","year":"2012","unstructured":"Barrett MP, Croft SL. Management of trypanosomiasis and leishmaniasis. Br Med Bull. 2012;104:175\u201396.","journal-title":"Br Med Bull."},{"key":"1051_CR3","unstructured":"Drugs for Neglected Diseases Initiative Foundation. Phase II\/III studies show high efficacy and safety of fexinidazole, the first oral treatment for sleeping sickness [media release]. \n                    http:\/\/www.dndi.org\n                    \n                  . 04 Nov 2017."},{"key":"1051_CR4","unstructured":"Sanofi. Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment [media release]. 31 Jan 2018."},{"key":"1051_CR5","unstructured":"European Medicine Agency. Medicines for use outside the European Union. 2018. \n                    https:\/\/www.ema.europa.eu\n                    \n                  . Accessed 06 Dec 2018."},{"key":"1051_CR6","unstructured":"European Medicines Agency. Fexinidazole Winthrop: summary of opinion. \n                    https:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 15 Nov 2018."},{"key":"1051_CR7","unstructured":"Sanofi. European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness [media release]. \n                    http:\/\/hugin.info\/152918\/R\/2226012\/873418.pdf\n                    \n                  . 17 Nov 2018."},{"key":"1051_CR8","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT01980199. 2015. \n                    https:\/\/clinicaltrials.gov\n                    \n                  . Accessed 07 Jan 2019."},{"key":"1051_CR9","unstructured":"Drugs for Neglected Diseases initiative. Donors. 2018. \n                    https:\/\/www.dndi.org\/donate\/donors\n                    \n                  . Accessed 07 Jan 2019."},{"key":"1051_CR10","unstructured":"World Health Organization. Human African trypanosomiasis. Symptoms, diagnosis and treatment. 2018. \n                    https:\/\/www.who.int\/trypanosomiasis_african\/disease\/diagnosis\/en\/\n                    \n                  . Accessed 07 Jan 2019."},{"issue":"12","key":"1051_CR11","doi-asserted-by":"publisher","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","volume":"4","author":"E Torreele","year":"2010","unstructured":"Torreele E, Trunz BB, Tweats D, et al. Fexinidazole \u2013 a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4(12):e923.","journal-title":"PLoS Negl Trop Dis."},{"issue":"12","key":"1051_CR12","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1128\/AAC.00246-11","volume":"55","author":"M Kaiser","year":"2011","unstructured":"Kaiser M, Bray MA, Cal M, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011;55(12):5602\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"1051_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijantimicag.2017.01.038","volume":"50","author":"H Burrell-Saward","year":"2017","unstructured":"Burrell-Saward H, Harris AJ, de LaFlor R, et al. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis. Int J Antimicrob Agents. 2017;50(2):203\u20139.","journal-title":"Int J Antimicrob Agents."},{"issue":"11","key":"1051_CR14","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","volume":"6","author":"MT Bahia","year":"2012","unstructured":"Bahia MT, de Andrade IM, Martins TA, et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis. 2012;6(11):e1870.","journal-title":"PLoS Negl Trop Dis."},{"key":"1051_CR15","doi-asserted-by":"publisher","first-page":"35351","DOI":"10.1038\/srep35351","volume":"6","author":"AF Francisco","year":"2016","unstructured":"Francisco AF, Jayawardhana S, Lewis MD, et al. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Sci Rep. 2016;6:35351.","journal-title":"Sci Rep."},{"issue":"119","key":"1051_CR16","doi-asserted-by":"publisher","first-page":"119re1","DOI":"10.1126\/scitranslmed.3003326","volume":"4","author":"S Wyllie","year":"2012","unstructured":"Wyllie S, Patterson S, Stojanovski L, et al. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med. 2012;4(119):119re1.","journal-title":"Sci Transl Med"},{"key":"1051_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1051\/parasite\/2013038","volume":"20","author":"M Dethoua","year":"2013","unstructured":"Dethoua M, Nzoumbou-Boko R, Truc P, et al. Evaluation of trypanocidal drugs used for human African trypanosomosis against Trypanosoma lewisi. Parasite. 2013;20:39.","journal-title":"Parasite."},{"issue":"5","key":"1051_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1365-3156.1996.tb00084.x","volume":"1","author":"FW Jennings","year":"1996","unstructured":"Jennings FW, Atouguia JM, Murray M. Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436. Trop Med Int Health. 1996;1(5):590\u20138.","journal-title":"Trop Med Int Health."},{"issue":"5","key":"1051_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/mutage\/ges015","volume":"27","author":"D Tweats","year":"2012","unstructured":"Tweats D, Trunz BB, Torreele E. Genotoxicity profile of fexinidazole \u2013 a drug candidate in clinical development for human African trypanosomiasis (sleeping sickness). Mutagenesis. 2012;27(5):523\u201332.","journal-title":"Mutagenesis."},{"issue":"6","key":"1051_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40262-014-0136-3","volume":"53","author":"A Tarral","year":"2014","unstructured":"Tarral A, Blesson S, Mordt OV, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet. 2014;53(6):565\u201380.","journal-title":"Clin Pharmacokinet."},{"issue":"10116","key":"1051_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","volume":"391","author":"V Mesu","year":"2018","unstructured":"Mesu V, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144\u201354.","journal-title":"Lancet."},{"issue":"Suppl. 1","key":"1051_CR22","first-page":"337","volume":"20","author":"A Signorell","year":"2015","unstructured":"Signorell A, Torrente M, Scherrer B, et al. Safety and efficacy of fexinidazole against rhodesiense human African trypanosomiasis: approach to conducting a clinical trial for a very rare, neglected disease [abstract no. PS2.088]. Trop Med Int Health. 2015;20(Suppl. 1):337.","journal-title":"Trop Med Int Health"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-1051-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-1051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-1051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T00:11:51Z","timestamp":1578701511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-1051-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-1051-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"11 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}